# A Study to Assess TTI-0102 vs Placebo in MELAS Patients

> **NCT06644534** · PHASE2 · RECRUITING · sponsor: **Thiogenesis Therapeutics, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- MELAS Syndrome
- Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)

## Interventions

- **DRUG:** TTI-0102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06644534
- **Lead sponsor:** Thiogenesis Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-12
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06644534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06644534, "A Study to Assess TTI-0102 vs Placebo in MELAS Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06644534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*